Rasonque Drug Costs $500K Yet Offers Hope | US News

A groundbreaking new drug for advanced pancreatic cancer, Rasonque, is hitting the market at a jaw-dropping $500,000 annually—but it nearly doubles survival time, extending median life to 13.2 months versus 6.7 with chemo. The company justifies the price as value-driven and promises free access for uninsured patients meeting criteria, while insurers will shoulder most of the cost. This isn’t unprecedented—several 2024 cancer drugs already exceed $400K/year, a stark contrast to the $100K+ “luxury” treatments of two decades ago. Insurers are already reviewing coverage, but strict rules could still block access for some. With a track record of providing free care before approval, the real test is whether this life-extending treatment remains within reach for those who need it most. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/04d75fecf3ee9a5a